Objective: To assess longitudinal expression of a proliferation-inducing ligand (APRIL) in patients with systemic lupus erythematosus (SLE) and its correlation with B lymphocyte stimulator (BLyS) expression, serum anti-dsDNA titres, and clinical disease activity.
Methods: Sixty eight patients with SLE were longitudinally followed up for a median of 369 days. At each visit the physician assessed disease activity by SLEDAI, and blood was collected for determination of serum APRIL and BLyS levels and of blood APRIL and BLyS mRNA levels. Fifteen normal control subjects underwent similar laboratory evaluation.
Results: Dysregulation of APRIL was not as great as that of BLyS. Changes in serum levels of APRIL and BLyS over time were usually discordant, whereas blood levels of APRIL and BLyS mRNA strongly paralleled each other. Serum APRIL levels modestly, but significantly, inversely correlated with serum anti-dsDNA titres in anti-dsDNA positive patients analysed in aggregate. Moreover, serum APRIL levels modestly, but significantly, inversely correlated with clinical disease activity in all patients analysed in aggregate.
Conclusion: Serum levels of APRIL and BLyS are differentially regulated. APRIL may serve as a down modulator of serological and/or clinical autoimmunity in patients with SLE. This may have important ramifications for BLyS targeted treatment, and it remains to be determined whether agents which neutralise only BLyS will be preferable to agents which neutralise both BLyS and APRIL.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1755113 | PMC |
| http://dx.doi.org/10.1136/ard.2003.018663 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of telitacicept in IgA nephropathy: a real-world study.
Ren Fail
December 2025
Division of Nephrology, Department of Medicine, West China Hospital, Sichuan University, Chengdu, China.
Background: IgA nephropathy (IgAN) is the most common primary glomerular disease in the world, and specific therapeutic methods for IgAN are limited. Telitacicept is a humanized fusion protein composed of a transmembrane activator and calcium-modulating cyclophilin ligand interactor receptor and human IgG.
Aim: To evaluate the efficacy and safety of telitacicept in adult patients with IgAN in a real-world study.
The emerging role of BLyS/APRIL in autoimmune diseases: Biological characteristics, functions, and therapeutic potential.
J Autoimmun
December 2024
Department of Pathology, The Second Affiliated Hospital of Anhui Medical University, 678 Furong Road, Hefei, Anhui, 230601, China; Department of Pathology, School of Basic Medical Sciences, Anhui Medical University, 81 Meishan Road, Hefei, Anhui, 230032, China. Electronic address:
Autoimmune diseases (AIDs) are common diseases in the world. Some cases are difficult to cure and can only delay the progression of the diseases. The B lymphocyte stimulator (BLyS)/a proliferation-inducing ligand (APRIL) plays an important role in B cell homeostasis, regulation of both innate and adaptive immune responses.
View Article and Find Full Text PDFA first-in-human, randomized study of the safety, pharmacokinetics and pharmacodynamics of povetacicept, an enhanced dual BAFF/APRIL antagonist, in healthy adults.
Clin Transl Sci
November 2024
Alpine Immune Sciences, a Vertex Company, Seattle, Washington, USA.
Therapeutic agents targeting the tumor necrosis factor (TNF) superfamily cytokines B-cell activating factor (BAFF, BLyS) and/or A PRoliferation Inducing Ligand (APRIL) have demonstrated clinical effectiveness in multiple autoimmune diseases, such as systemic lupus erythematosus, lupus nephritis, and immunoglobulin A nephropathy (IgAN). However, their clinical utility can often be limited by incomplete and/or prolonged times to clinical response and inconvenient dosing regimens, which may be improved by more potent dual inhibition of both cytokines. Povetacicept (ALPN-303; TACI vTD-Fc) is a crystallizable fragment (Fc) fusion protein of an engineered transmembrane activator and CAML interactor (TACI) domain which mediates more potent inhibitory activity than wild-type TACI-Fc or BAFF- or APRIL-specific antibodies and demonstrates superior pharmacokinetic and pharmacodynamic activity in multiple preclinical disease models.
View Article and Find Full Text PDFCombination treatment with telitacicept, mycophenolate mofetil and glucocorticoids for immunoglobulin A nephropathy: A case report.
World J Clin Cases
October 2024
Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang 550002, Guizhou Province, China.
Article Synopsis
- Telitacicept helps reduce B cell activation and abnormal IgA antibody production, protecting the kidneys from damage in IgA nephropathy.
- A 24-year-old female with IgA nephropathy showed significant improvement in renal function and reduced proteinuria after starting treatment with telitacicept, despite prior treatments failing.
- Combining telitacicept with other therapies may be a safe and effective option for treating IgA nephropathy.
Efficacy and safety of telitacicept, a BLyS/APRIL dual inhibitor, in the treatment of IgA nephropathy: a retrospective case-control study.
Clin Kidney J
October 2024
Department of Nephrology, First Hospital of China Medical University, Shenyang, Liaoning Province, China.
Article Synopsis
- - The study evaluated the safety and effectiveness of telitacicept, a drug targeting B lymphocytes, in treating immunoglobulin A nephropathy (IgAN) in 42 patients, comparing results across three different treatment groups: a whole telitacicept group, a newly treated subgroup, and a conventional immunosuppressive (IS) group.
- - After 24 weeks, both the newly treated telitacicept subgroup and the conventional IS group showed significant reductions in 24-hour proteinuria (a measure of protein in urine), with improvements in the estimated glomerular filtration rate (eGFR), indicating better kidney function.
- - Overall, while all three groups demonstrated improvements, no serious
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!